Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Dec 24;3(4):48-53.
doi: 10.5500/wjt.v3.i4.48.

Current status of clinical islet transplantation

Andrew R Pepper  1 , Boris Gala-Lopez  1 , Oliver Ziff  1 , Am James Shapiro  1
Affiliations

Current status of clinical islet transplantation

Andrew R Pepper et al. World J Transplant. .

Abstract

Islet transplantation (IT) is today a well-established treatment modality for selected patients with type 1 diabetes mellitus (T1DM). After the success of the University of Alberta group with a modified approach to the immune protection of islets, the international experience grew along with the numbers of transplants in highly specialized centers. Yet, long-term analysis of those initial results from the Edmonton group indicated that insulin-independence was not durable and most patients return to modest amounts of insulin around the fifth year, without recurrent hypoglycemia events. Many phenomena have been identified as limiting factor for the islet engraftment and survival, and today all efforts are aimed to improve the quality of islets and their engrafting process, as well as more optimized immunosuppression to facilitate tolerance and ultimately, better long term survival. This brief overview presents recent progress in IT. A concise historical perspective is provided, along with the latest efforts to improve islet engraftment, immune protection and ultimately, prolonged graft survival. It is apparent that as the community continues to work together further optimizing IT, it is hopeful a cure for T1DM will soon be achievable.

Keywords: Immunosuppression; Islet transplantation; Type 1 diabetes.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Total number of recent islet allograft infusion per recipient per donor in CITR-participating centers (2004-2010). Data adapted from 2010 CITR Seventh Annual Report.
See this image and copyright information in PMC

References

    1. Ryan EA, Bigam D, Shapiro AM. Current indications for pancreas or islet transplant. Diabetes Obes Metab. 2006;8:1–7. - PubMed
    1. Shapiro AM, Ricordi C, Hering BJ, Auchincloss H, Lindblad R, Robertson RP, Secchi A, Brendel MD, Berney T, Brennan DC, et al. International trial of the Edmonton protocol for islet transplantation. N Engl J Med. 2006;355:1318–1330. - PubMed
    1. Shapiro AM, Lakey JR, Ryan EA, Korbutt GS, Toth E, Warnock GL, Kneteman NM, Rajotte RV. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med. 2000;343:230–238. - PubMed
    1. Jahansouz C, Jahansouz C, Kumer SC, Brayman KL. Evolution of β-cell replacement therapy in diabetes mellitus: Islet cell transplantation. J Transplant. 2011;2011:247959. - PMC - PubMed
    1. Shapiro J, Shaw J. A historical perspective on experimental and clinical islet transplantation. In: Shapiro AMJ, Shaw JAM, editors. Islet transplantation and beta cell replacement therapy. New York: Informa Healthcare; 2007. pp. 1–28.